Abstracts tagged "Eye Disorders"

Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Uwe Pleyer¹, Salem Almutairi², Conor Murphy³, Rola Hamam⁴, Karina Julian⁵, Shereen Hammad⁶, Orsolya Nagy⁷, Zohar Habot-Wilner⁸, Zsuzsanna Szepessy⁹, Yan Guex-Crosier¹⁰ and Sofia Androudi¹¹, ¹Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany, ²Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait, ³Royal Victoria Eye & Ear Hospital, Dublin, Ireland, ⁴American University of Beirut, Beirut, Lebanon, ⁵Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁶AbbVie Biopharmaceuticals GmbH, Dubai, United Arab Emirates, ⁷AbbVie Kft, Budapest, Hungary, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, ¹¹University of Thessaly, Larissa, Greece
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…
Abstract Number: 1307 • ACR Convergence 2020
Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial Spondyloarthritis with Deep Learning
Yun Ju Huang¹, Chang-Fu Kuo², Yu Huei Huang³, Yih Shiou Hwang⁴ and Chihung Lin⁵, ¹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan (Republic of China), ²Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ³Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁴Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China)
Background/Purpose: Fundoscopy is essential to identify the retinopathy of patients with autoimmune diseases. However, the classification of different autoimmune diseases is difficult by human eyes…
Abstract Number: 0406 • ACR Convergence 2020
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo², Vanesa Calvo-Río³, Emma Beltran-Catalan⁴, Alfredo Adan⁵, Marisa Hernandez Garfella⁶, Elia Valls-Pascual⁷, Agustín Sellas-Fernández⁸, N Ortego⁹, Alejandro Fonollosa¹⁰, Olga Maiz Alonso¹¹, Ignacio Torre¹², Cruz Fernández-Espartero¹³, Vega Jovani¹⁴, Diana Peiteado¹⁵, David Díaz Valle¹⁶, Susana Romero-Yuste¹⁷, Elena Aurrecoechea¹, Miriam García-Arias¹⁸, Miguel Ángel Caracuel¹⁹, Santos Insúa²⁰, Senén González-Suárez²¹, Amalia Sánchez Andrade²², Luis Francisco Linares²³, Alfredo J García González²⁴, Raquel Almodovar²⁵, Carmen Carrasco Cubero²⁶, María Alcalde Villar²⁷, C Fernandez-Carballido²⁸, Fred A Pages²⁹, Eva Peña Sainz-Pardo²⁴, Rosalia Demetrio-Pablo³, Santos Castañeda³⁰, Miguel Ángel González-Gay³¹, José Luis Hernández³ and Ricardo Blanco³, ¹Hospital Sierrallana, Torrelavega, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Del Mar University Hospital, Barcelona, ⁵Hospital Clinic, Barcelona, Catalonia, Spain, ⁶H. Valencia, Valencia, Spain, ⁷H. Doctor Peset, Valencia, Spain, ⁸H. Vall d'Hebron, Barcelona, Spain, ⁹H. San Cecilio, Granada, Spain, ¹⁰H. de Cruces, Bilbao, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹²Hospital Basurto, Bilbao, Spain, ¹³H. Mostoles, Madrid, Spain, ¹⁴H. Alicante, Alicante, Spain, ¹⁵Hospital La Paz - IdiPAZ, Madrid, Spain, ¹⁶H. Clínico San Carlos, Madrid, Spain, ¹⁷H Pontevedra, Coruna, Spain, ¹⁸H. La Princesa, Madrid, ¹⁹H.U. Reina Sofía, Córdoba, Spain, ²⁰H. Santiago de Compostela, Santiago de Compostela, Spain, ²¹H. Cabueñes, Gijón, Spain, ²²H. Lucus Augusti, Lugo, Spain, ²³Hospital de la Arrixaca, Murcia, ²⁴H. 12 de Octubre, Madrid, Spain, ²⁵Fundación Alcorcón University Hospital, Madrid, ²⁶H. Mérida, Mérida, Spain, ²⁷H. Severo Ochoa, Madrid, Spain, ²⁸H San Juan, Alicante, Spain, ²⁹H. Palencia, Palencia, Spain, ³⁰Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
Abstract Number: 1817 • ACR Convergence 2020
Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus
Laura Pelegrin¹, Marc Figueras-Roca¹, Alvaro Olate-Perez¹, Javier Zarranz-Ventura¹, Ricardo Casaroli-Marano¹, Montse Morató¹, Vanesa Budi¹, José Ríos², Ricard Cervera³, Alfredo Adan¹ and Gerard Espinosa¹, ¹Hospital Clinic, Barcelona, Catalonia, Spain, ²Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Eye involvement in systemic lupus erythematosus (SLE) occurs in approximately one-third of patients, usually related to disease activity. An early diagnosis and treatment could…
Abstract Number: 0460 • ACR Convergence 2020
Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
Michael Paley¹, Lynn Hassman¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Grace Paley¹, Jennifer Laurent¹, Luke Springer¹, Lacey Feigl¹, Maxim Artyomov¹ and Wayne Yokoyama², ¹Washington University, Saint Louis, ²Washington University, St Louis, MO
Background/Purpose: Anterior uveitis is a form of ocular inflammation associated with rheumatologic disease and can be categorized as granulomatous or non-granulomatous. Whether different ocular manifestations…
Abstract Number: 1945 • ACR Convergence 2020
Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
Hussein Baalbaki¹, Darya Jalaledin², Catherine Lachance² and Jean-Paul Makhzoum³, ¹Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Universite de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background/Purpose: Permanent vision loss (PVL) is a feared complication and a leading cause of morbidity in Giant Cell Arteritis (GCA). Multiple risk factors for ocular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].